Abstract

Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM)

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
High Rate of Sustained Minimal Residual Disease Negativity Predicts Prolonged Survival for the Overall Patient Population in the Phase 2 KRd Plus Autologous Stem Cell Transplantation MMRC Trial
...
Blood | VOL. 130
, et. al. ...
25 Jun 2021
Minimal Residual Disease Evaluation By Multiparameter Flow Cytometry and Next Generation Sequencing in the Forte Trial for Newly Diagnosed Multiple Myeloma Patients
Stefania Oliva ...
Blood | VOL. 134
Stefania Oliva, et. al.Stefania Oliva ...
13 Nov 2019
Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update
Kenneth H Shain ...
Blood | VOL. 134
Kenneth H Shain, et. al.Kenneth H Shain ...
13 Nov 2019
Impact of Minimal Residual Disease (MRD) By Multiparameter Flow Cytometry (MFC) and Next-Generation Sequencing (NGS) on Outcome: Results of Newly Diagnosed Transplant-Eligible Multiple Myeloma (MM) Patients Enrolled in the Forte Trial
Stefania Oliva ...
Blood | VOL. 136
Stefania Oliva, et. al.Stefania Oliva ...
05 Nov 2020
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Herpetic lymphadenitis mimicking Richter transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma
Samuel Bidot ... Andrew L Feldman
Blood | VOL. 143
Samuel Bidot, et. al.Samuel Bidot ... Andrew L Feldman
27 Jun 2024
GM-CSF brings (good) memories
Damien Reynaud
Blood | VOL. 143
Damien ReynaudDamien Reynaud
27 Jun 2024
Introduction to a review series on oncogenic signaling and immune evasion in hematologic malignancies
Robert Zeiser
Blood | VOL. 143
Robert ZeiserRobert Zeiser
27 Jun 2024
Crespiatico I, Zaghi M, Mastini C, et al. First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis. Blood. 2024;143(14):1399-1413.
-
Blood | VOL. 143
--
27 Jun 2024
View more papers